Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Nov 4, 2010

Premium

Title: Treatment or Prevention of Oto-Pathologies by Inhibition of Pro-Apoptotic Genes

Patent Number: 7,825,099

Filed: Jan. 18, 2007

Inventor: Elena Feinstein, Quark Pharmaceuticals

"The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes," the patent's abstract states. "The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier.

"The … invention also contemplates a method of treating or preventing the incidence or severity of hearing impairment or balance impairment, particularly hearing impairment associated with cell death of the inner ear hair cells or outer ear hair cells, comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient," it adds.


Title: Specific GRP78 Expression-Inhibition Sequence, Medicine Thereof, and Method Thereof

Patent Number: 7,825,100

Filed: April 30, 2009

Lead Inventor: Ann-Joy Cheng, Chang Gung University

The invention comprises "a specific GRP78 expression-inhibition RNAi sequence, a medicine thereof, and a method thereof, wherein an RNAi sequence … complementary to GRP78 forms a special hairpin structure inside cancer cells to specifically and effectively inhibit GRP78 expression and then inhibit the canceration process, including the growth, migration, invasion, and metastasis of cancer," the patent's abstract states.


Title: Modulation of MLCK-L Expression and Uses Thereof

Patent Number: 7,825,101

Filed: Aug. 30, 2007 PCT Filed: Aug. 30, 2007

Lead Inventor: Dolly Mehta, University of Illinois

"In various aspects and embodiments, the invention provides methods and reagents for controlling gene expression, and for treating disorders and diseases," according to the patent's abstract. "Embodiments provide methods and reagents specifically for the regulation of MLCK expression and for the use thereof in treating disorders and diseases. Various embodiments provide methods and reagents for specifically down-regulating the expression of MLCK-L more efficiently than that of MLCK-S, and for the use thereof in treating disorders and diseases.

"Embodiments provide siNA for the same, particularly siRNAs … [and] are useful for the treatment of inflammatory disorders and diseases, including, for one example … asthma," it adds.


Title: Lung Cancer-Related Nucleic Acids

Patent Number: 7,825,229

Filed: May 4, 2006

Lead Inventor: Isaac Bentwich, Rosetta Genomics

The patent, its abstract states, claims "polynucleotides associated with lung cancer. The polynucleotides are miRNAs, miRNA precursors, and associated nucleic acids.

"Methods and compositions are described that can be used for diagnosis, prognosis, and treatment of lung cancer," it notes. "Also described are methods that can be used to identify modulators of the disease-associated polynucleotides … [as well as] methods and compositions for linear amplification and labeling of a targeted nucleic acid. The amplified targeted molecules may be used in hybridization techniques like Luminex and microarray analysis."


Title: Human microRNA Targets in HIV Genome and a Method of Identification Thereof

Patent Number: 7,825,230

Filed: Oct. 10, 2006

Lead Inventor: Samir Kumar Brahmachari, Institute of Genomics and Integrative Biology

The invention "relates to human microRNA targets in [the] HIV genome and a method of identification thereof," the patent's abstract states. "Targets to six human microRNAs were discovered in the net, vpr, env, and I vif genes. The miRNAs were identified as hsa-miR-29a, hsa-miR-29b, hsa-miR-29c, hsa-mir-149, hsa-mir-324-5p, [and] hsa-mir-378. These miRNAs or [their] homologues can be used as therapeutics against HIV infection.

"The invention further relates to a novel strategy to target genes of HIV-1 by human microRNAs, or its homologues, to inactivate or block HIV activity," the abstract adds. "The computational approach towards identification of human miRNA targets in the HIV genome and the variation in the microRNA levels was further validated experimentally."


Title: Therapeutic Uses of Inhibitors of RTP801

Application Number: 20100272722

Filed: Jan. 18, 2007

Lead Inventor: Elena Feinstein, Quark Pharmaceuticals

The invention provides "novel molecules, compositions, methods, and uses for treating microvascular disorders, eye diseases, respiratory conditions, and hearing disorders based upon inhibition of the RTP801 gene and/or protein," the patent application's abstract states.


Title: Nanoparticle-Mediated Treatment for Inflammatory Diseases

Application Number: 20100272813

Filed: July 23, 2008 PCT Filed: July 23, 2008

Lead Inventor: Jorgen Kjems, Aarhus University

The invention provides "nanoparticles for treatment of inflammatory diseases," the patent application's abstract states. "The nanoparticles preferably comprise chitosan and an siRNA targeting a mRNA encoding a pro-inflammatory cytokine," such as TNF-alpha. "A preferred route of administration of the nanoparticles is by injection intraperitoneally."


Title: Human microRNAs and Methods for Inhibiting [the] Same

Application Number: 20100273255

Filed: May 1, 2006 PCT Filed: May 1, 2006

Lead Inventor: Thomas Tuschl, Rockefeller University

"The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a [specific] sequence in a microRNA … except that up to thirty percent of the bases may be wobble bases, and up to 10 [percent] of the contiguous bases may be non-complementary," according to the patent application's abstract. The invention further relates to modified single-stranded microRNA molecules, isolated single-stranded anti-microRNA molecules, and isolated microRNP molecules. In another embodiment, the invention relates to a method for inhibiting microRNP activity in a cell."


Title: Oncogenomics-Based RNAi Screen and Uses Thereof to Identify Novel Tumor Suppressors

Application Number: 20100273660

Filed: Nov. 12, 2009

Lead Inventor: Lars Zender, Cold Spring Harbor Laboratory

"In some aspects, the invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma," the patent application's abstract states. "The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal.

The invention also provides "methods for identifying and validating tumor suppressor genes by screening pools of shRNAs that target genomic regions deleted in human cancers, such as human hepatocellular carcinomas," the abstract adds. "The … invention also provides validated tumor suppressor genes, and methods of inhibiting cell proliferation and/or tumor growth, for example by expression of such tumor suppressor genes."


Title: Compositions and Methods for Inhibiting NADPH Oxidase Expression

Application Number: 20100273854

Filed: June 12, 2008 PCT Filed: June 12, 2008

Lead Inventor: Hagar Kalinski, Quark Pharmaceuticals

The patent application, its abstract states, claims "one or more inhibitors, in particular siRNAs, [that] down-regulate the expression of a NOX gene selected from the group consisting of NOX4, NOXI, NOX2, NOX5, DUOX2, NOXOI, NOXAI and NOXA2. … Also provided is a vector capable of expressing the compound … [as well as] a method … for treating or preventing the incidence or severity of various diseases or conditions associated with NOX gene comprising administering to the patient the inhibitor in a pharmaceutical composition."


Title: Screening of microRNA Cluster Inhibitor Pools

Application Number: 20100273856

Filed: July 21, 2008 PCT Filed: July 21, 2008

Lead Inventor: Anja Smith, Dharmacon (Thermo Fisher Scientific)

The invention, the patent application's abstract states, comprises "methods for inhibiting the activity of a miRNA cluster in a cell, and also for screening a cell for phenotypes of interest resulting from inhibition of a miRNA cluster. The methods use a cluster pool [that] comprises at least one miRNA inhibitor specific for each miRNA in the miRNA cluster."

The application further describes "miRNA inhibitors … that induce apoptosis in breast cancer cells and hence are useful in the treatment of breast cancer," the abstract notes. "The disclosure also provides pharmaceutical compositions which are useful for the treatment of breast cancer; methods for inducing the nuclear translocation of NF-kappa B in a breast cancer cell; methods for inducing the nuclear translocation of c-Jun in a breast cancer cell; method for inhibiting the nuclear translocation of NF-kappa B in a breast cancer cell; and methods for providing prognostic medical information relating to breast cancer progression."


Title: Compositions Comprising STAT5 siRNA and Methods of Use Thereof

Application Number: 20100273858

Filed: Sept. 17, 2008 PCT Filed: Sept. 17, 2008

Lead Inventor: Frank Xie, Intradigm

The invention "provides nucleic acid molecules that inhibit STAT5 expression," according to the patent application's abstract. "Methods of using the nucleic acid molecules are also provided."


Title: Modulation of Gene Expression Using Oligomers that Target Gene Regions Downstream of 3' Untranslated Regions

Application Number: 20100273863

Filed: April 23, 2010

Lead Inventor: David Corey, University of Texas

"Gene expression can be selectively modulated by contacting a cell with an oligomer that targets a gene region downstream of a '3-UTR, thereby increasing or decreasing the expression of the target gene," the patent application's abstract states.


Title: Methods and Compositions for Modulating Tissue Factor

Application Number: 20100273998

Filed: Feb. 22, 2010

Lead Inventor: Hans Prydz, University of Oslo

The invention "features nucleic acid molecules, specifically short interfering RNA molecules, that are able to modulate the expression of TF and methods for using such molecules for the treatment of coagulative disorders and for the prevention and treatment of cancer," the patent application's abstract states.

The Scan

CDC Calls Delta "Variant of Concern"

CNN reports the US Centers for Disease Control and Prevention now considers the Delta variant of SARS-CoV-2 to be a "variant of concern."

From FDA to Venture Capital

Former FDA Commissioner Stephen Hahn is taking a position at a venture capital firm, leading some ethicists to raise eyebrows, according to the Washington Post.

Consent Questions

Nature News writes that there are questions whether informed consent was obtained for some submissions to a database of Y-chromosome profiles.

Cell Studies on Multimodal Single-Cell Analysis, Coronaviruses in Bats, Urban Microbiomes

In Cell this week: approach to analyze multimodal single-cell genomic data, analysis of bat coronaviruses, and more.